Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$1.98 USD
-0.04 (-1.98%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.97 -0.01 (-0.51%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XERS 1.98 -0.04(-1.98%)
Will XERS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Why Xeris (XERS) Might Surprise This Earnings Season
Other News for XERS
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Xeris Biopharma price target lowered by $1 at Piper Sandler, here's why
Piper Sandler Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Xeris Pharmaceuticals (XERS) Receives a Buy from Oppenheimer